A single-arm, Phase II clinical study protocol of Apatolimab Tovolimab in combination with regorafenib and chemotherapy as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
Willing to participate in this study and has signed the informed consent form.
Age greater than 18 years, regardless of gender.
Histologically confirmed unresectable locally advanced or metastatic G/GEJ adenocarcinoma.
No prior systemic treatment for unresectable locally advanced or metastatic G/GEJ adenocarcinoma. Previous neoadjuvant and/or adjuvant therapy is acceptable, but all systemic treatments must have been completed at least 6 months prior to the diagnosis of unresectable or metastatic disease.
Known HER2-positive expression (immunohistochemistry [IHC] 3+ or 2+ with a fluorescence in situ hybridization HER2:CEP17 ratio ≥2).
Presence of other malignancies within 5 years prior to treatment, with the exception of adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, locally treated prostate cancer, and ductal carcinoma in situ (hormone therapy for non-metastatic prostate cancer or breast cancer is permitted).
Known central nervous system metastases and/or carcinomatous meningitis.
Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction.
Single group
Iparomlimab and Tuvonralimab combination with regorafenib and chemotherapy
DrugIparomlimab and Tuvonralimab：5mg/kg，Intravenous infusion，Q3W regorafenib：80mg，oral administration once daily from Day 1 to Day 14 chemotherapy：XELOX or SOX
Objective response rate
Progression-free survival (PFS)
Disease control rate (DCR)
Duration of response (DoR)
Overall survival (OS)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
